S-a descoperit că o pastilă poate aproape dubla perioada de supraviețuire pentru pacienții cu cancer pancreatic avansat, experții descriind studiul clinic ca fiind revoluționar.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease